BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18069279)

  • 21. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.
    Freiberger JJ; Padilla-Burgos R; Chhoeu AH; Kraft KH; Boneta O; Moon RE; Piantadosi CA
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1321-7. PubMed ID: 17577496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses.
    Morris M; Cruickshank S
    Eur J Oncol Nurs; 2010 Jul; 14(3):205-10. PubMed ID: 20129822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
    Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
    Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 25. Complication related to bisphosphonate therapy: osteonecrosis of the jaw.
    Lee J
    J Infus Nurs; 2009; 32(6):330-5. PubMed ID: 19918142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 27. A review of the clinical implications of bisphosphonates in dentistry.
    Borromeo GL; Tsao CE; Darby IB; Ebeling PR
    Aust Dent J; 2011 Mar; 56(1):2-9. PubMed ID: 21332734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
    Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
    Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
    Carmagnola D; Celestino S; Abati S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural history of osteonecrosis of the jaw in patients with multiple myeloma.
    Badros A; Terpos E; Katodritou E; Goloubeva O; Kastritis E; Verrou E; Zervas K; Baer MR; Meiller T; Dimopoulos MA
    J Clin Oncol; 2008 Dec; 26(36):5904-9. PubMed ID: 19018084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
    Sarasquete ME; González M; San Miguel JF; García-Sanz R
    Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.
    Montazeri AH; Erskine JG; McQuaker IG
    Eur J Haematol; 2007 Jul; 79(1):69-71. PubMed ID: 17598839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 36. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 37. Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists.
    Chaturvedi P; Pai PS; Chaukar DA; Gupta S; D'cruz AK
    Eur J Surg Oncol; 2010 Jun; 36(6):541-5. PubMed ID: 20071132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
    Goranova-Marinova VS; Pechalova-Petrova PF; Goranov SG
    Folia Med (Plovdiv); 2009; 51(4):53-7. PubMed ID: 20232660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.